Holy $CLRX Shares Outstanding 2,929,954 a/o Nov
Post# of 23098
Posted On: 02/03/2015 9:26:39 AM
Re: SmallCapTraders #2862
Holy $CLRX Shares Outstanding 2,929,954 a/o Nov 12, 2014
Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued By BrokerBank Securities, Inc.
NEW YORK, Feb. 3, 2015 /PRNewswire via COMTEX/ -- Littany Lane Investments analyst initiates coverage of CollabRx, Inc. (NASDAQ: CLRX) with near term price target of $2.50-$3.50/share. CollabRx recently announced an LOI to merge with Medytox Solutions on January 22nd, 2015. Medytox could potentially add over $52.5M in annual revenue to CollabRx's bottom line based on the most recent annual report issued by Medytox (Year ending December 31st, 2013).
A full analyst report with a company highlights, description of company products, recent events, outlook, analyst summary, price target and recommendation can be viewed by using link below.
It should be noted that this recent analyst coverage and price target does not include the potential revenues Medytox brings to the table should the merger be completed. There is no cost obligation required to view analyst brief:
http://bit.ly/-CLRX-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA� and Chartered Financial Analyst� are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number 130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/littany-lane-investments-analyst-initiates-coverage-of-collabrx-with-near-term-target-of-2-350-issued-by-brokerbank-securities-inc-300029614.html
SOURCE BrokerBank Securities, Inc.
http://rt.prnewswire.com/rt.gif?NewsItemId=DE...d=20150203
www.prnewswire.com
Copyright (C) 2015 PR Newswire. All rights reserved
-0-
KEYWORD: New York
INDUSTRY KEYWORD: FIN
SUBJECT CODE: TNM
INO
OTC
Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50 Issued By BrokerBank Securities, Inc.
NEW YORK, Feb. 3, 2015 /PRNewswire via COMTEX/ -- Littany Lane Investments analyst initiates coverage of CollabRx, Inc. (NASDAQ: CLRX) with near term price target of $2.50-$3.50/share. CollabRx recently announced an LOI to merge with Medytox Solutions on January 22nd, 2015. Medytox could potentially add over $52.5M in annual revenue to CollabRx's bottom line based on the most recent annual report issued by Medytox (Year ending December 31st, 2013).
A full analyst report with a company highlights, description of company products, recent events, outlook, analyst summary, price target and recommendation can be viewed by using link below.
It should be noted that this recent analyst coverage and price target does not include the potential revenues Medytox brings to the table should the merger be completed. There is no cost obligation required to view analyst brief:
http://bit.ly/-CLRX-AnalystReport
Copy and paste to browser may be required.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Not Financial Advice
BrokerBank Securities, Inc. make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
CFA� and Chartered Financial Analyst� are registered trademarks owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number 130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/littany-lane-investments-analyst-initiates-coverage-of-collabrx-with-near-term-target-of-2-350-issued-by-brokerbank-securities-inc-300029614.html
SOURCE BrokerBank Securities, Inc.
http://rt.prnewswire.com/rt.gif?NewsItemId=DE...d=20150203
www.prnewswire.com
Copyright (C) 2015 PR Newswire. All rights reserved
-0-
KEYWORD: New York
INDUSTRY KEYWORD: FIN
SUBJECT CODE: TNM
INO
OTC
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'